StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) revenue by segment

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)

Close on Nov 17, 2026Market cap $96.14MP/E –Yield –

InMed Pharmaceuticals Inc. revenue by segment

Periods

By business segment

Operating incomeFY2026CY2026FY2025CY2025FY2024CY2024FY2023CY2023FY2022CY2022YoY
BayMedica–––-$1.21M-$5.19M–
InMed–––-$6.74M-$13.41M–

By product or service

By region

From the segment and revenue-disaggregation notes of InMed Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to InMed Pharmaceuticals's operating metrics, with full history, charts and a link to each filing.

See a number that looks wrong?